OTCMKTS:ABCZY Abcam (ABCZY) Stock Forecast, Price & News Add Compare Share Share Today's Range N/A50-Day Range$19.40▼$19.4052-Week Range N/AVolume5,400 shsAverage Volume4,712 shsMarket Capitalization$3.98 billionP/E RatioN/ADividend Yield0.36%Price TargetN/A ProfileProfileChartCompetitorsHeadlinesShort InterestProfileChartCompetitorsHeadlinesShort Interest About Abcam (OTCMKTS:ABCZY) StockAbcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.Read More ABCZY Stock News HeadlinesSeptember 28, 2023 | msn.comAbcam founder slams £4.5bn sale to US conglomerate DanaherSeptember 28, 2023 | ca.news.yahoo.comUK Life Sciences Firm Abcam’s Founder Fights $5.7 Billion BidSeptember 30, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 15, 2023 | msn.comUPDATE 3-Abcam founder seeks to block $5.7 billion Danaher dealSeptember 15, 2023 | msn.comSignal: Danaher’s $5.7bn acquisition of Abcam faces stand-off with founderSeptember 14, 2023 | finance.yahoo.comAbcam plc Statement on Dr. Jonathan Milner’s AnnouncementSeptember 14, 2023 | thetimes.co.ukAbcam founder Jonathan Milner renews clear-out bidSeptember 14, 2023 | investing.comAbcam plc founder to vote against proposed $5.7B Danaher acquisition, believes offer undervalues the companySeptember 30, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 14, 2023 | finance.yahoo.comDr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace BoardSeptember 14, 2023 | investing.comAbcam founder Jonathan Milner opposes Danaher dealSeptember 14, 2023 | ft.comAbcam founder to vote against proposed $5.7bn acquisition by US DanaherSeptember 6, 2023 | thetimes.co.ukAbcam founder calls on board to justify takeover bidAugust 31, 2023 | msn.comAbcam founder, holder Jonathan Milner still evaluating Danaher deal - reportAugust 29, 2023 | markets.businessinsider.comDanaher's Strategic Abcam Deal Boosts Growth at a Reasonable Price: AnalystAugust 29, 2023 | msn.comDanaher agrees to acquire UK’s Abcam for $5.7bnAugust 28, 2023 | thetimes.co.ukAbcam agrees $5.7bn US takeover dealAugust 28, 2023 | msn.comUS medical giant Danaher lands UK life-science firm Abcam in £4.5bn dealAugust 28, 2023 | msn.comAbcam holder Milner expects to speak to holders next week on Danaher deal - reportAugust 28, 2023 | msn.comBritish biotech firm Abcam snapped up by Danaher for £4.5bnAugust 28, 2023 | technews.tmcnet.comDanaher to Acquire AbcamAugust 28, 2023 | za.investing.comDanaher to acquire Abcam for $5.7 billionAugust 28, 2023 | technews.tmcnet.comDanaher to acquire Abcam for $24.00 per ShareAugust 22, 2023 | markets.businessinsider.comExpert Ratings for AbcamJuly 12, 2023 | finance.yahoo.comAbcam plc: All Resolutions Withdrawn at Abcam's EGMJuly 5, 2023 | bizjournals.comBiotech supplier Abcam is closing its 2nd Bay Area location this year and cutting 43 more workersJune 27, 2023 | msn.comAbcam founder Jonathan Milner suspends proxy solicitation (update)See More Headlines Receive ABCZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Industrial Inorganic Chemicals Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ABCZY Previous SymbolNASDAQ:ABCZY CUSIPN/A CIKN/A Webwww.abcam.com Phone44 1223 696 000FaxN/AEmployees1,492Year Founded1998Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$336.37 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares205,080,000Free FloatN/AMarket Cap$3.98 billion OptionableNot Optionable Beta1.29 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Alan Thomas Hirzel BS (Age 52)MS, MBA, CEO & Exec. Director Mr. Michael Shaun Baldock (Age 54)CFO & Director Dr. Jonathan Simon Milner (Age 55)Co-Founder & Non-Exec. Deputy Chairman Mr. Mark DermodyInterim CIOJames StaveleyVP of Investor RelationsKey CompetitorsNeogenNASDAQ:NEOGAspen PharmacareOTCMKTS:APNHYMerit Medical SystemsNASDAQ:MMSIACADIA PharmaceuticalsNASDAQ:ACADDoximityNASDAQ:DOCSView All Competitors ABCZY Stock - Frequently Asked Questions Is Abcam a good dividend stock? Abcam (OTCMKTS:ABCZY) pays an annual dividend of $0.07 per share and currently has a dividend yield of 0.36%. Read our dividend analysis for ABCZY. What is Abcam's stock symbol? Abcam trades on the OTCMKTS under the ticker symbol "ABCZY." How do I buy shares of Abcam? Shares of ABCZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Abcam make? Abcam (OTCMKTS:ABCZY) has a market capitalization of $0.00 and generates $336.37 million in revenue each year. How many employees does Abcam have? The company employs 1,492 workers across the globe. Does Abcam have any subsidiaries? The following companies are subsidiares of Abcam: Abcam (US) Ltd., Abcam Trading (Shanghai) Co. Ltd., Abcam US Group Holdings Inc., and Epitomics Inc.Read More How can I contact Abcam? The official website for the company is www.abcam.com. The company can be reached via phone at 44 1223 696 000. This page (OTCMKTS:ABCZY) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abcam plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.